专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO9412670A3 PROCESS FOR TYPING OF HCV ISOLATES 审中-公开
标题翻译：分离型HCV的方法
公开(公告)号：WO9412670A3
公开(公告)日：1994-07-21
申请号：PCT/EP9303325
申请日：1993-11-26
申请人： INNOGENETICS NV , MAERTENS GEERT , STUYVER LIEVEN , ROSSAU RUDI , HEUVERSWYN HUGO VAN
发明人： MAERTENS GEERT , STUYVER LIEVEN , ROSSAU RUDI , VAN HEUVERSWYN HUGO
IPC分类号： C12N15/09 , C07H21/04 , C12N15/40 , C12Q1/02 , C12Q1/68 , C12Q1/70 , C12M9/34
CPC分类号： C12Q1/707 , C12Q1/6834 , C12Q2563/131 , C12Q2545/101 , C12Q2525/101 , C12Q2531/113
摘要： The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position -291 to nucleotide at position -66 of the 5' untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes; detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be identified.

2. 发明申请

WO9740193A2 METHOD FOR TYPING AND DETECTING HBV 审中-公开
标题翻译： HBV的筛选和检测方法
公开(公告)号：WO9740193A2
公开(公告)日：1997-10-30
申请号：PCT/EP9702002
申请日：1997-04-21
申请人： INNOGENETICS NV , STUYVER LIEVEN , ROSSAU RUDI , MAERTENS GEERT
发明人： STUYVER LIEVEN , ROSSAU RUDI , MAERTENS GEERT
IPC分类号： C12N15/36 , C12Q1/70
CPC分类号： C12Q1/706
摘要： The present invention relates to a method for detection and/or genetic analysis of HBV in a biological sample, comprising hybridizing the polynucleic acids of the sample with a combination of at least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from Figure 1, and with said probes being applied to known locations on a solid support and with said probes being capable of hybridizing to the polynucleic acids of the sample under the same hybridization and wash conditions, or with said probes hybridizing specifically with a sequence complementary to any of said target sequences, or a sequence wherein T of said target sequence is replaced by U; and detecting the hybrids formed; and inferring the HBV genotype and/or mutants present in said sample from the differential hybridization signal(s) obtained. The invention further relates to sets of nucleotide probes and possibly primers useful in said methods as well as to their use in a method for typing and/or detecting HBV and to assay kits using the same.
摘要翻译：本发明涉及用于生物样品中HBV的检测和/或遗传分析的方法，包括将所述样品的多核酸与至少两个核苷酸探针的组合杂交，所述组合特异性与选择的突变靶序列杂交从HBV RT pol基因区和/或选自HBV preCore区的突变靶序列和/或选自HBV的HBsAg区和/或HBV基因型特异性靶序列的突变靶序列，其中所述靶序列选自图1，并且将所述探针应用于固体支持物上的已知位置，并且所述探针能够在相同的杂交和洗涤条件下与样品的多核酸杂交，或者与所述探针特异性杂交具有与任何所述靶序列互补的序列，或其中所述靶序列的T被U替代的序列; 并检测形成的杂种; 并从所获得的差异杂交信号中推断存在于所述样品中的HBV基因型和/或突变体。本发明还涉及可用于所述方法的核苷酸探针和可能的引物的集合，以及它们在用于分型和/或检测HBV的方法中的用途以及使用其的测定试剂盒。

3. 发明申请

WO0104358A3 DETECTION OF ANTI-HEPATITIS B DRUG RESISTANCE 审中-公开
标题翻译：检测抗乙型肝炎药物耐药性
公开(公告)号：WO0104358A3
公开(公告)日：2001-08-30
申请号：PCT/EP0006306
申请日：2000-07-05
申请人： INNOGENETICS NV , STUYVER LIEVEN , MAERTENS GEERT , GEYT CAROLINE VAN
发明人： STUYVER LIEVEN , MAERTENS GEERT , VAN GEYT CAROLINE
IPC分类号： C12N15/09 , C12Q20060101 , C12Q1/68 , C12Q1/70
CPC分类号： C12Q1/706
摘要： The present invention relates to a method for the monitoring of anti-HBV drug resistance in a patient by genetic detection of at least one of the mutations L528M, M552V/I and/or V/L/M555I in the DNA polymerase of the HBV strains present in a biological sample of said patient. The present invention provides new HBV DNA polymerase sequences to be used for the design of new probes allowing a very specific and sensitive detection of anti-HBV drug resistance.
摘要翻译：本发明涉及通过遗传检测HBV株DNA聚合酶中的至少一个突变L528M，M552V / I和/或V / L / M555I来监测患者抗HBV耐药性的方法存在于所述患者的生物样品中。本发明提供新的HBV DNA聚合酶序列，用于设计新的探针，允许对抗HBV耐药性的非常特异和灵敏的检测。

4. 发明申请

WO9613590A2 NEW SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USE AS PROPHYLACTIC, THERAPEUTIC AND DIAGNOSTIC AGENTS 审中-公开
标题翻译：丙型肝炎病毒基因组的新序列及其作为预防，治疗和诊断代理的用途
公开(公告)号：WO9613590A2
公开(公告)日：1996-05-09
申请号：PCT/EP9504155
申请日：1995-10-23
申请人： INNOGENETICS NV , MAERTENS GEERT , STUYVER LIEVEN
发明人： MAERTENS GEERT , STUYVER LIEVEN
IPC分类号： G01N33/53 , A61K38/00 , A61K38/08 , A61K38/10 , A61K39/00 , A61K39/29 , A61K39/395 , A61K48/00 , A61P1/16 , A61P31/12 , A61P31/14 , A61P37/04 , C07H21/00 , C07K4/02 , C07K7/06 , C07K7/08 , C07K14/18 , C07K16/08 , C07K16/10 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/11 , C12N15/40 , C12N15/51 , C12P21/02 , C12Q1/68 , C12Q1/70 , G01N33/543 , G01N33/566 , G01N33/569 , G01N33/576 , G01N33/577
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/525 , C12N2770/24222
摘要： The present invention relates to new genomic nucleotide sequences and amino acid sequences corresponding to the coding region of these genomes. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes sequences. More particularly, the present invention relates to new HCV type 7 sequences, new HCV type 9 sequences, new HCV type 10 and new HCV type 11 sequences. Also, the present invention relates to new HCV type 1 sequences of subtypes 1d, 1e, 1f and 1g; new HCV type 2 sequences of subtypes 2e, 2f, 2g, 2h, 2i, 2k and 2l; new HCV type 3 sequences of subtype 3g, new HCV type 4 sequences of subtypes 4k, 4l and 4m; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the Core, the E1 and the NS5 regions of new HCV types 7, 9, 10 and 11, as well as of new variants (subtypes) of HCV types 1, 2, 3 and 4. These new HCV sequences are useful to diagnose the presence of HCV type 1, and/or type 2, and/or type 3, and/or type 4, and/or type 7, and/or type 9, and/or type 10, and/or type 11 genotypes or serotypes in a biological sample. Moreover, the availability of these new type-specific sequences can increase the overall sensitivity of HCV detection and should also prove to be useful for prophylactic and therapeutic purposes.
摘要翻译：本发明涉及对应于这些基因组的编码区的新的基因组核苷酸序列和氨基酸序列。本发明涉及与已知的HCV类型和亚型序列不同的新的HCV类型和亚型序列。更具体地，本发明涉及新的HCV 7型序列，新型HCV 9型序列，新型HCV 10型和新型HCV 11型序列。此外，本发明涉及新型的1型，1e，1f和1g型新型HCV 1型序列; 亚型2e，2f，2g，2h，2i，2k和2l的新HCV 2型序列; 亚型3g的新型HCV 3型序列，亚型4k，4l和4m的新型HCV 4型序列; 它们的制备过程及其用于诊断，预防和治疗。更具体地，本发明提供新型HCV 7型，9型，10型和11型的核心，E1和NS5区域的新型特异性序列，以及HCV类型1,2和2的新变体（亚型）这些新的HCV序列可用于诊断HCV 1型和/或2型和/或3型和/或4型和/或7型和/或9型的存在，以及 /或10型，和/或11型基因型或血清型。此外，这些新型特异性序列的可用性可以增加HCV检测的总体灵敏度，并且还应证明可用于预防和治疗目的。

5. 发明申请

WO9425601A3 NEW SEQUENCES OF HEPATITIS C VIRUS GENOTYPES AND THEIR USE AS THERAPEUTIC AND DIAGNOSTIC AGENTS 审中-公开
标题翻译：丙型肝炎病毒基因组的新序列及其作为治疗和诊断试剂的使用
公开(公告)号：WO9425601A3
公开(公告)日：1995-03-02
申请号：PCT/EP9401323
申请日：1994-04-27
申请人： INNOGENETICS NV , MAERTENS GEERT , STUYVER LIEVEN
发明人： MAERTENS GEERT , STUYVER LIEVEN
IPC分类号： G01N33/50 , A61K31/711 , A61K31/713 , A61K35/76 , A61K38/00 , A61K39/00 , A61K39/395 , A61K48/00 , A61P1/16 , A61P31/12 , A61P31/14 , A61P31/20 , C07K14/02 , C07K14/10 , C07K14/18 , C07K16/00 , C07K16/08 , C07K16/10 , C12N15/09 , C12N15/40 , C12N15/41 , C12N15/51 , C12Q1/68 , C12Q1/70 , G01N33/15 , G01N33/53 , G01N33/566 , G01N33/576 , A61K39/29 , C07N14/18
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N2770/24222
摘要： The present invention relates to new polynucleic acid and amino acid sequences corresponding to new HCV type 5 sequences. The present invention also relates to the use of these polynucleic acids and amino acids in methods or processes for the detection of one or more HCV genotypes, or for the preparation of antibodies against new HCV type 5 polypeptides. The invention also includes compositions comprising said polynucleic acid and amino acid sequences. The present invention further relates to kits comprising polynucleic acid probes and/or primers defined by the invention, or comprising polypeptides according to the invention.

6. 发明申请

WO9829442A9 ANNEXIN V-BINDING POLYPEPTIDES DERIVED FROM HBsAg AND THEIR USES 审中-公开
标题翻译：来自HBsAg及其用途的新型V-结合多肽
公开(公告)号：WO9829442A9
公开(公告)日：2000-02-17
申请号：PCT/EP9707268
申请日：1997-12-23
申请人： INNOGENETICS NV , DEPLA ERIK , MAERTENS GEERT , YAP SING HIEN , MEYER SANDRA DE
发明人： DEPLA ERIK , MAERTENS GEERT , YAP SING-HIEN , DE MEYER SANDRA
IPC分类号： G01N33/53 , A61K39/00 , A61K39/29 , A61K39/395 , A61P31/20 , C07K14/02 , C07K16/08 , G01N33/15 , G01N33/566 , G01N33/576
CPC分类号： C07K14/005 , A61K39/00 , C12N2730/10122
摘要： Polypeptides derived from hepatitis B surface antigen which are able to compete with the hepatitis B surface antigen/annexin V interaction, or which are able to bind a compound or antibody competing with the hepatitis B surface antigen/annexin V interaction are described. The use of these polypeptides, and antibodies against them, in order to diagnose, treat and vaccinate against an infection with hepatitis B virus and/or hepatitis delta virus is also disclosed.
摘要翻译：描述了能够与乙型肝炎表面抗原/膜联蛋白V相互作用竞争或能够结合与乙型肝炎表面抗原/膜联蛋白V相互作用竞争的化合物或抗体的乙型肝炎表面抗原的多肽。还公开了使用这些多肽和抗体的抗体来诊断，治疗和接种乙型肝炎病毒和/或乙型肝炎病毒感染。

7. 发明申请

WO9604385A3 PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE 审中-公开
标题翻译：纯化的乙型肝炎病毒包膜蛋白用于诊断和治疗用途
公开(公告)号：WO9604385A3
公开(公告)日：1996-03-07
申请号：PCT/EP9503031
申请日：1995-07-31
申请人： INNOGENETICS NV , MAERTENS GEERT , BOSMAN FONS , MARTYNOFF GUY DE , BUYSE MARIE ANGE
发明人： MAERTENS GEERT , BOSMAN FONS , DE MARTYNOFF GUY , BUYSE MARIE-ANGE
IPC分类号： G01N33/53 , A61K38/00 , A61K39/00 , A61K39/29 , A61K39/395 , A61P1/16 , A61P31/12 , C07K14/18 , C07K16/10 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/02 , C12N15/09 , C12N15/40 , C12P21/00 , C12P21/02 , C12P21/08 , C12Q1/70 , C12R1/865 , C12R1/91 , C12R1/92 , G01N33/576 , G01N33/577 , G01N33/569
CPC分类号： C07K16/109 , A61K39/00 , A61K39/12 , A61K39/29 , A61K2039/5256 , C07K14/005 , C07K2317/34 , C12N2710/24143 , C12N2770/24222 , C12N2770/24234 , C12N2770/24243 , Y10S435/803 , Y10S435/81 , Y10S435/915 , Y10S435/975
摘要： The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.

8. 发明申请

WO02055548A3 PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE 审中-公开
标题翻译：纯化的乙型肝炎病毒包膜蛋白用于诊断和治疗用途
公开(公告)号：WO02055548A3
公开(公告)日：2004-08-05
申请号：PCT/EP0200219
申请日：2002-01-11
申请人： INNOGENETICS NV , MAERTENS GEERT , BOSMAN FONS , BUYSE MARIE-ANGE
发明人： MAERTENS GEERT , BOSMAN FONS , BUYSE MARIE-ANGE
IPC分类号： A61K39/00 , C07K14/18 , C12N15/40 , A61K39/29 , C12Q1/70 , G01N33/576
CPC分类号： C07K14/005 , A61K39/00 , C12N2710/24143 , C12N2770/24222
摘要： The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic ad therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome if HCV treatment.
摘要翻译：本发明涉及一种纯化选自E1和/或E2和/或E1 / E2的重组HCV单一或特异性寡聚包膜蛋白的方法，其特征在于在裂解转化的宿主细胞以分离重组表达的蛋白质二硫键裂解或还原步骤用二硫键切割剂进行。本发明还涉及通过这种方法分离的组合物。本发明还涉及这些组合物的诊断和治疗应用。此外，本发明涉及HCV E1蛋白和肽在HCV治疗中用于预测和监测临床有效性和/或临床结果的用途。

9. 发明申请

WO2004041853A3 HCV VACCINE COMPOSITIONS COMPRISING E1 AND NS3 PEPTIDES 审中-公开
标题翻译：包含E1和NS3肽的HCV疫苗组合物
公开(公告)号：WO2004041853A3
公开(公告)日：2004-07-15
申请号：PCT/EP0312394
申请日：2003-11-06
申请人： INNOGENETICS NV , MAERTENS GEERT , DEPLA ERIK , D HONDT ERIK
发明人： MAERTENS GEERT , DEPLA ERIK , D HONDT ERIK
IPC分类号： A61K39/29 , C07K14/18
CPC分类号： C07K14/005 , A61K39/12 , A61K39/29 , A61K2039/525 , A61K2039/5258 , A61K2039/55505 , A61K2039/57 , C12N2770/24222 , C12N2770/24234
摘要： The invention relates to immunogenic and vaccine compositions useful in prophylactic and therapeutic treatment of HCV infection. More specifically, said compositions comprise a HCV envelope peptide E1 and a HCV non-structural peptide NS3.
摘要翻译：本发明涉及可用于预防和治疗HCV感染的免疫原性和疫苗组合物。更具体地说，所述组合物包含HCV包膜肽E1和HCV非结构肽NS3。

10. 发明申请

WO03051912A2 PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE 审中-公开
标题翻译：纯化的乙型肝炎病毒包膜蛋白用于诊断和治疗用途
公开(公告)号：WO03051912A2
公开(公告)日：2003-06-26
申请号：PCT/EP0214480
申请日：2002-12-18
申请人： INNOGENETICS NV , MAERTENS GEERT , DEPLA ERIK , BOSMAN FONS
发明人： MAERTENS GEERT , DEPLA ERIK , BOSMAN FONS
IPC分类号： G01N33/53 , A61K38/00 , A61K39/00 , A61K39/29 , A61K39/395 , A61P1/16 , A61P31/12 , C07K14/18 , C12N15/09 , C12N15/40
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N2770/24222
摘要： The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.
摘要翻译：本发明涉及一种纯化选自E1和/或E2和/或E1 / E2的重组HCV单一或特异性寡聚包膜蛋白的方法，其特征在于在裂解转化的宿主细胞以分离重组表达的蛋白质二硫键裂解或还原步骤用二硫键切割剂进行。本发明还涉及通过这种方法分离的组合物。本发明还涉及这些组合物的诊断和治疗应用。此外，本发明涉及HCV E1蛋白和肽用于预测和监测HCV治疗的临床有效性和/或临床结果的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式